METHODS OF MAINTAINING OR INCREASING GROWTH OR COGNITIVE DEVELOPMENT

• US 20110009349A1
• Filed: 10/20/2008
• Published: 01/13/2011
• Est. Priority Date: 10/19/2007
• Status: Abandoned Application

• Current Assignee: Fonterra Company-Operative Group Limited
• Original Assignee: Fonterra Company-Operative Group Limited
• Inventors: Vickers, Mark Hedley, McJarrow, Christopher Paul, Todd, Joanne Margaret, Mitchell, Murray D., Rowan, Angela Marie, Hodgkinson, Steven Charles
• Application Number:
  US12/682,582
• Publication Number:
  US 20110009349A1
• Time in Patent Office: Days
• US Class Current: 514/25
• CPC Class Codes: A23C 2240/05 Milk products enriched with milk fat globule membrane
• CPC Class Codes: A23D 9/007 characterised by ingredients other than fatty acid triglycerides
• CPC Class Codes: A23D 9/013 Other fatty acid esters, e.g. phosphatides
• CPC Class Codes: A23L 33/115 Fatty acids or derivatives thereof; Fats or oils
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/322 having an effect on the health of the nervous system or on mental function
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

One or more complex lipids including gangliosides to achieve particular health benefits including maintaining or increasing cognitive development or maintaining or increasing growth in a foetal, infant or child subject.

Claims

1-28. -28. (canceled)

29. A method for maintaining or increasing growth of a foetal, infant, or child subject, the method comprising administering one or more complex lipids to a foetal, infant, or child subject in need thereof, wherein the one or more complex lipids comprises at least about 0.1% gangliosides w/w on a dry basis.

30. The method of claim 29, wherein the one or more complex lipids are administered to a mother during gestation and the growth is brain weight of a foetal subject or brain ganglioside content of a foetal subject.

31. The method of claim 29, wherein the one or more complex lipids are administered to an infant or child subject and the growth is one or more of body weight, body length, and bone mineral density.

36. The method of claim 29, wherein the one or more complex lipids comprises one or more phospholipids, one or more sphingolipids, one or more sphingomyelins or derivatives thereof, one or more ceramides, one or more cerebrosides, one or more gangliosides, or any combination of any two or more thereof.

37. The method of claim 36, wherein the one or more gangliosides comprises GM3, GD3, or a mixture of at least GM3 and GD3.

38. The method of claim 29, wherein the one or more complex lipids are administered in a composition comprising at least about 2 mg gangliosides per, 100 g or about 5 mg to about 20 mg gangliosides per 100 g.

40. The method of claim 29, wherein the one or more complex lipids comprises a milk fat extract.

41. The method of claim 40, wherein the milk fat extract comprises about 15% to about 99% by weight total lipid, about 1% to about 80% by weight phospholipid, about 1% to about 25% by weight phosphatidylcholine, about 0.1% to about 15% by weight phosphatidylinositol, about 0.1% to about 15% by weight phosphatidylserine, about 1% to about 30% by weight phosphatidylethanolamine, about 0.5% to about 25% by weight sphingomyelin, and about 0.1 to about 10% by weight ganglioside.

42. The method of claim 41, wherein the one or more complex lipids are administered in a composition comprising at least about 2 mg milk fat extract per 100 g, at least about 5 mg milk fat extract per 100 g, or at least about 7.5 mg milk fat extract per 100 g.

48. The method of claim 29, wherein the one or more complex lipids comprises a milk fat extract.

49. The method of claim 48, wherein the milk fat extract comprises about 15% to about 99% by weight total lipid, about 1% to about 80% by weight phospholipid, about 1% to about 25% by weight phosphatidylcholine, about 0.1% to about 15% by weight phosphatidylinositol, about 0.1% to about 15% by weight phosphatidylserine, about 1% to about 30% by weight phosphatidylethanolamine, about 0.5% to about 25% by weight sphingomyelin, and about 0.1 to about 10% by weight ganglioside.

50. The method of claim 49, wherein the one or more complex lipids are administered in a composition comprising at least about 2 mg milk fat extract per 100 g, at least about 5 mg milk fat extract per 100 g, or at least about 7.5 mg milk fat extract per 100 g.

51. The method of claim 29, wherein the one or more complex lipids comprises

(a) about 15 to about 25% w/w lipid, about 5 to about 15% w/w phospholipid, and about 0.1 to about 1% w/w ganglioside, or

(b) about 15 to about 25% w/w lipid, about 5 to about 15% w/w phospholipid, about 1 to about 5% w/w phosphatidylcholine, about 0.1 to about 2% w/w phosphatidylinositol, about 0.5 to about 2% w/w phosphatidylserine, about 1.5 to about 6% w/w phosphatidylethanolamine, about 1 to about 5% w/w sphingomyelin, and about 0.1 to about 1% w/w ganglioside, or

(c) about 25 to about 45% w/w lipid, about 10 to about 25% w/w phospholipid, and about 0.1 to about 2.0% w/w ganglioside, or

(d) about 25 to about 45% w/w lipid, about 10 to about 25% w/w phospholipid, about 1 to about 5% w/w phosphatidylcholine, about 0.1 to 2% w/w phosphatidylinositol, about 0.5 to about 2% w/w phosphatidylserine, about 1.5 to about 6% w/w phosphatidylethanolamine, about 1 to about 5% w/w sphingomyelin, and about 0.1 to about 2.0% w/w ganglioside, or

(e) about 12 to about 32% w/w lipid, about 5 to about 25% w/w phospholipid, and about 0.1 to about 2.0% w/w ganglioside, or

(f) about 12 to about 32% w/w lipid, about 5 to about 25% w/w phospholipid, about 2 to about 8% w/w phosphatidylcholine, about 0.5 to 3% w/w phosphatidylinositol, about 1 to about 3.5% w/w phosphatidylserine, about 1 to about 10% w/w phosphatidylethanolamine, about 1 to about 8% w/w sphingomyelin, and about 0.5 to about 2.5% w/w ganglioside, or

(g) about 80 to about 99% w/w lipid, about 20 to about 75% w/w phospholipid, and about 0.5 to about 5% w/w ganglioside, or

(h) about 80 to about 99% w/w lipid, about 20 to about 75% w/w phospholipid, about 2 to about 22% w/w phosphatidylcholine, about 1 to about 10% w/w phosphatidylinositol, about 1 to about 10% w/w phosphatidylserine, about 5 to about 30% w/w phosphatidylethanolamine, about 1 to about 20% w/w sphingomyelin, and about 0.5 to about 5% w/w ganglioside, or

(i) about 90 to about 99% w/w lipid, about 20 to about 40% w/w phospholipid, and about 0.5 to about 5% w/w ganglioside, or

(j) about 80 to about 99% w/w lipid, about 60 to about 80% w/w phospholipid, and about 0.5 to about 5% w/w ganglioside, or

(k) about 15 to about 45% w/w lipid, about 8 to about 25% w/w phospholipid, and about 0.1 to about 5% w/w ganglioside, or

(l) about 15 to about 45% w/w lipid, about 8 to about 25% w/w phospholipid, about 1 to about 5% w/w phosphatidylcholine, about 1 to about 5% w/w phosphatidylinositol, about 2 to about 8% w/w phosphatidylserine, about 2 to about 8% w/w phosphatidylethanolamine, about 0.5 to about 5% w/w sphingomyelin, and about 0.1 to about 5% w/w ganglioside, or

(m) about 50 to about 99% w/w lipid, about 15 to about 60% w/w phospholipid, and about 1 to about 10% w/w ganglioside, or

(n) about 50 to about 99% w/w lipid, about 15 to about 60% w/w phospholipid, about 1 to about 10% w/w phosphatidylcholine, about 1 to about 15% w/w phosphatidylinositol, about 1 to about 20% w/w phosphatidylserine, about 1 to about 20% w/w phosphatidylethanolamine, about 1 to about 10% w/w sphingomyelin, and about 0.1 to about 10% w/w ganglioside.

32. A method for maintaining or increasing cognitive development of a foetal, infant, or child subject by administering a one or more complex lipids to a foetal, infant, or child subject in need thereof, wherein the one or more complex lipids comprises at least about 0.1% gangliosides w/w on a dry basis.

33. The method of claim 32, wherein the one or more complex lipids are administered to a mother during gestation and the cognitive development is brain weight of a foetal subject or brain ganglioside content of a foetal subject.

45. The method of claim 32, wherein the one or more complex lipids comprises one or more phospholipids, one or more sphingolipids, one or more sphingomyelins or derivatives thereof, one or more ceramides, one or more cerebrosides, one or more gangliosides, or any combination of any two or more thereof.

46. The method of claim 45, wherein the one or more gangliosides comprises GM3, GD3, or a mixture of at least GM3 and GD3.

47. The method of claim 32, wherein the one or more complex lipids are administered in a composition comprising at least about 2 mg gangliosides per 100 g or about 5 mg to about 20 mg gangliosides per 100 g.

34. A method for maintaining or increasing growth or maintaining or increasing cognitive development of a foetal subject, the method comprising providing a pregnant mother with one or more complex lipids and informing the mother that the one or more complex lipids will maintain or increase growth or maintain or increase cognitive development of the foetal subject, wherein the one or more complex lipids comprises at least about 0.1% gangliosides w/w on a dry basis.

35. A method for maintaining or increasing growth or maintaining or increasing cognitive development in a subject, the method comprising providing a subject with one or more complex lipids and informing the subject that the one or more complex lipids will maintain or increase growth or maintain or increase cognitive development of the subject, wherein the one or more complex lipids comprises at least about 0.1% gangliosides w/w on a dry basis.

39. (canceled)

43. (canceled)

44. (canceled)